165 related articles for article (PubMed ID: 25397901)
1. Structure-guided DOT1L probe optimization by label-free ligand displacement.
Yi JS; Federation AJ; Qi J; Dhe-Paganon S; Hadler M; Xu X; St Pierre R; Varca AC; Wu L; Marineau JJ; Smith WB; Souza A; Chory EJ; Armstrong SA; Bradner JE
ACS Chem Biol; 2015 Mar; 10(3):667-74. PubMed ID: 25397901
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
Zhang L; Chen Y; Liu N; Li L; Xiao S; Li X; Chen K; Luo C; Chen S; Chen H
Bioorg Chem; 2018 Oct; 80():649-654. PubMed ID: 30059890
[TBL] [Abstract][Full Text] [Related]
6. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
[TBL] [Abstract][Full Text] [Related]
7. In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors.
Zhu B; Zhang H; Pan S; Wang C; Ge J; Lee JS; Yao SQ
Chemistry; 2016 Jun; 22(23):7824-36. PubMed ID: 27115831
[TBL] [Abstract][Full Text] [Related]
8. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
Yu W; Chory EJ; Wernimont AK; Tempel W; Scopton A; Federation A; Marineau JJ; Qi J; Barsyte-Lovejoy D; Yi J; Marcellus R; Iacob RE; Engen JR; Griffin C; Aman A; Wienholds E; Li F; Pineda J; Estiu G; Shatseva T; Hajian T; Al-Awar R; Dick JE; Vedadi M; Brown PJ; Arrowsmith CH; Bradner JE; Schapira M
Nat Commun; 2012; 3():1288. PubMed ID: 23250418
[TBL] [Abstract][Full Text] [Related]
9. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
Basavapathruni A; Jin L; Daigle SR; Majer CR; Therkelsen CA; Wigle TJ; Kuntz KW; Chesworth R; Pollock RM; Scott MP; Moyer MP; Richon VM; Copeland RA; Olhava EJ
Chem Biol Drug Des; 2012 Dec; 80(6):971-80. PubMed ID: 22978415
[TBL] [Abstract][Full Text] [Related]
10. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
Raj U; Kumar H; Gupta S; Varadwaj PK
Asian Pac J Cancer Prev; 2015; 16(9):3817-25. PubMed ID: 25987043
[TBL] [Abstract][Full Text] [Related]
11. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
Chen J; Park HJ
ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
[TBL] [Abstract][Full Text] [Related]
12. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
Anglin JL; Song Y
J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
[TBL] [Abstract][Full Text] [Related]
13. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
[TBL] [Abstract][Full Text] [Related]
14. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
[TBL] [Abstract][Full Text] [Related]
16. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays.
Chen S; Li L; Chen Y; Hu J; Liu J; Liu YC; Liu R; Zhang Y; Meng F; Zhu K; Lu J; Zheng M; Chen K; Zhang J; Jiang H; Yao Z; Luo C
J Chem Inf Model; 2016 Mar; 56(3):527-34. PubMed ID: 26914852
[TBL] [Abstract][Full Text] [Related]
18. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
Gibbons GS; Chakraborty A; Grigsby SM; Umeano AC; Liao C; Moukha-Chafiq O; Pathak V; Mathew B; Lee YT; Dou Y; Schürer SC; Reynolds RC; Snowden TS; Nikolovska-Coleska Z
Eur J Med Chem; 2020 Mar; 189():112023. PubMed ID: 31978781
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
Wang Y; Li L; Zhang B; Xing J; Chen S; Wan W; Song Y; Jiang H; Jiang H; Luo C; Zheng M
J Med Chem; 2017 Mar; 60(5):2026-2036. PubMed ID: 28165739
[TBL] [Abstract][Full Text] [Related]
20. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
Waters NJ; Daigle SR; Rehlaender BN; Basavapathruni A; Campbell CT; Jensen TB; Truitt BF; Olhava EJ; Pollock RM; Stickland KA; Dovletoglou A
J Control Release; 2015 Dec; 220(Pt B):758-65. PubMed ID: 26385168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
